302 related articles for article (PubMed ID: 28287273)
1. Novel monoclonal treatments in severe asthma.
Meteran H; Meteran H; Porsbjerg C; Backer V
J Asthma; 2017 Dec; 54(10):991-1011. PubMed ID: 28287273
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; MartÃnez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
3. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
4. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
Ohta K; Nagase H; Suzukawa M; Ohta S
Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
[TBL] [Abstract][Full Text] [Related]
5. Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies.
Pavord ID; Hanania NA
J Allergy Clin Immunol Pract; 2019; 7(5):1430-1436. PubMed ID: 30962155
[No Abstract] [Full Text] [Related]
6. Biologic targeted therapy in allergic asthma.
Bice JB; Leechawengwongs E; Montanaro A
Ann Allergy Asthma Immunol; 2014 Feb; 112(2):108-15. PubMed ID: 24468249
[TBL] [Abstract][Full Text] [Related]
7. Biologic agents for severe asthma patients: clinical perspectives and implications.
Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
[TBL] [Abstract][Full Text] [Related]
8. An update on biologic-based therapy in asthma.
Walsh GM
Immunotherapy; 2013 Nov; 5(11):1255-64. PubMed ID: 24188679
[TBL] [Abstract][Full Text] [Related]
9. Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.
Iyengar SR; Hoyte EG; Loza A; Bonaccorso S; Chiang D; Umetsu DT; Nadeau KC
Int Arch Allergy Immunol; 2013; 162(1):89-93. PubMed ID: 23816920
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of refractory asthma with antibodies].
Lommatzsch M
Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
[TBL] [Abstract][Full Text] [Related]
11. Severe asthma: what is new in the new millennium.
Ntontsi P; Samitas K; Zervas E; Gaga M
Curr Opin Allergy Clin Immunol; 2020 Apr; 20(2):202-207. PubMed ID: 32004177
[TBL] [Abstract][Full Text] [Related]
12. New Targeted Therapies for Uncontrolled Asthma.
Corren J
J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab in asthma: an update on recent developments.
Humbert M; Busse W; Hanania NA; Lowe PJ; Canvin J; Erpenbeck VJ; Holgate S
J Allergy Clin Immunol Pract; 2014; 2(5):525-36.e1. PubMed ID: 25213045
[TBL] [Abstract][Full Text] [Related]
14. Cytokines or their antagonists for the treatment of asthma.
O'Byrne PM
Chest; 2006 Jul; 130(1):244-50. PubMed ID: 16840409
[TBL] [Abstract][Full Text] [Related]
15. Future biologic therapies in asthma.
Quirce S; Bobolea I; DomÃnguez-Ortega J; Barranco P
Arch Bronconeumol; 2014 Aug; 50(8):355-61. PubMed ID: 24685200
[TBL] [Abstract][Full Text] [Related]
16. Anti-IgE and Biologic Approaches for the Treatment of Asthma.
Mitchell PD; El-Gammal AI; O'Byrne PM
Handb Exp Pharmacol; 2017; 237():131-152. PubMed ID: 27864676
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects.
de Roos EW; In 't Veen JC; Braunstahl GJ; Lahousse L; Brusselle GG
Drugs Aging; 2016 Sep; 33(9):619-28. PubMed ID: 27638817
[TBL] [Abstract][Full Text] [Related]
18. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma.
Mitchell PD; El-Gammal AI; O'Byrne PM
Clin Pharmacol Ther; 2016 Jan; 99(1):38-48. PubMed ID: 26502193
[TBL] [Abstract][Full Text] [Related]
19. Anti-IgE therapy: clinical utility and mechanistic insights.
Logsdon SL; Oettgen HC
Curr Top Microbiol Immunol; 2015; 388():39-61. PubMed ID: 25553794
[TBL] [Abstract][Full Text] [Related]
20. Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma.
Walsh GM
Expert Rev Respir Med; 2018 Nov; 12(11):957-963. PubMed ID: 30193532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
